Paradigm Financial Advisors adds Johnson & Johnson (JNJ) to its portfolio

Johnson & Johnson (JNJ) : Paradigm Financial Advisors added new position in Johnson & Johnson during the most recent quarter end. The investment management firm now holds 2,010 shares of Johnson & Johnson which is valued at $227,773 , the company said in a statement filed on Apr 21, 2016 with the SEC.Johnson & Johnson makes up approximately 0.14% of Paradigm Financial Advisors’s portfolio.

Johnson & Johnson closed down -0.14 points or -0.12% at $112.77 with 57,59,301 shares getting traded on Wednesday. Post opening the session at $112.96, the shares hit an intraday low of $112.46 and an intraday high of $113.2 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

Other Hedge Funds, Including , Gw Henssler Associates Ltd boosted its stake in JNJ in the latest quarter, The investment management firm added 937 additional shares and now holds a total of 117,935 shares of Johnson & Johnson which is valued at $13,364,394. Johnson & Johnson makes up approx 1.56% of Gw Henssler Associates Ltd’s portfolio.Fort Pitt Capital Group boosted its stake in JNJ in the latest quarter, The investment management firm added 20 additional shares and now holds a total of 21,536 shares of Johnson & Johnson which is valued at $2,440,460. Johnson & Johnson makes up approx 0.30% of Fort Pitt Capital Group’s portfolio.Burns J W Co Incny boosted its stake in JNJ in the latest quarter, The investment management firm added 432 additional shares and now holds a total of 60,539 shares of Johnson & Johnson which is valued at $6,596,935. Johnson & Johnson makes up approx 2.10% of Burns J W Co Incny’s portfolio.Trust Co Of Virginia Va boosted its stake in JNJ in the latest quarter, The investment management firm added 7,161 additional shares and now holds a total of 93,345 shares of Johnson & Johnson which is valued at $10,171,805. Johnson & Johnson makes up approx 1.85% of Trust Co Of Virginia Va’s portfolio.

On the company’s financial health, Johnson & Johnson reported $1.68 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Apr 19, 2016. Analyst had a consensus of $1.65. The company had revenue of $17482.00 million for the quarter, compared to analysts expectations of $17491.02 million. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.56 EPS.

Many Wall Street Analysts have commented on Johnson & Johnson. Company shares were Reiterated by RBC Capital Mkts on Apr 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 125 from a previous price target of $122 .Company shares were Reiterated by Piper Jaffray on Apr 20, 2016 to “Neutral”, Firm has raised the Price Target to $ 106 from a previous price target of $105 .Company shares were Reiterated by RBC Capital Mkts on Apr 15, 2016 to “Outperform”, Firm has raised the Price Target to $ 122 from a previous price target of $114 .

Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Company’s research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.

Leave a Reply

Johnson & Johnson - Is it time to Sell?

Top Brokerage Firms are advising their investors on Johnson & Johnson. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.